177Lu-PSMA-617 therapy specifically targets prostate cancer cells expressing prostate-specific membrane antigen (PSMA), a protein significantly overexpressed in malignant prostate tissue [30,31]. Here, FOLH1 is linked to Familial prostate cancer.